Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241522 · ClinicalTrials.gov registry record · Phase 1
Dosimetry of Tc-99m-Tilmanocept
A Phase 1 study of Diabetic Kidney Disease, sponsored by University of California, San Diego.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05241522: Recruiting Phase 1 study of Diabetic Kidney Disease, sponsored by University of California, San Diego.
NCT05241522 is a Phase 1 study of Diabetic Kidney Disease that is actively recruiting participants, run by University of California, San Diego. The registered enrollment target is 120 participants, below the 5,185-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05241522, a Phase 1 study of Diabetic Kidney Disease, is actively recruiting participants, sponsored by University of California, San Diego.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
This proposal will use kidney SPECT/CT of Tc-99m-tilmanocept to evaluate the mesangial changes seen in diabetics across the spectrum of kidney disease as well as persons with hypertensive kidney disease, the next most common cause of kidney disease in patients with diabetes. We aim to demonstrate that these different disease types and stages can be differentiated with Tc-99m-tilmanocept SPECT/CT and can thus be used for future trials evaluating early diagnosis and treatment of diabetic nephropathy.
Primary Outcome
Time until 90% uptake in the kidney measured by SPECT/CT immediately after tilmanocept injection.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Tc-99m-Tilmanocept
Study Locations (1)
California
- UC San Diego Medical Center - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2021-08-06 |
| Est. Completion | 2024-12-31 |
| Phase | Phase 1 |
What NCT05241522 shows while recruiting
NCT05241522 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 5,185-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Tc-99m-Tilmanocept is the first listed.
NCT05241522 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05241522 about?
NCT05241522 is a clinical study titled "Dosimetry of Tc-99m-Tilmanocept". This proposal will use kidney SPECT/CT of Tc-99m-tilmanocept to evaluate the mesangial changes seen in diabetics across the spectrum of kidney disease as well as persons with hypertensive kidney disease, the next most common cause of kidney disease in patients with diabetes. We aim to demonstrate th...
What is the current status of trial NCT05241522?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 120 participants. The study started on 2021-08-06. Estimated completion is 2024-12-31.
What conditions does trial NCT05241522 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease.
What interventions are being tested in trial NCT05241522?
The interventions under investigation include: Tc-99m-Tilmanocept (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT05241522?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05241522 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05241522's enrollment target sits among peer trials
120 10th of 23 higher than 13 of 23 other Diabetic Kidney Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetic Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
-
Impact of Metabolic Surgery on Pancreatic, Renal and Cardiovascular Health in Youth With Type 2 Diabetes
COMPLETED · Phase 1
-
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
RECRUITING
-
Formoterol in Diabetes
RECRUITING · Phase 2
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
A Long-Term Follow-Up Study of Participants Exposed to REACT
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI